Working… Menu

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02978716
Recruitment Status : Active, not recruiting
First Posted : December 1, 2016
Last Update Posted : January 27, 2021
Information provided by (Responsible Party):
G1 Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 30, 2018
Estimated Study Completion Date : May 2021
Certification/Extension First Submitted : July 18, 2019